TapewireFind a company

person · Reporting owner

Madden Martin J.

Disclosed activity across 2 companies

Tapewire entity
40918
SEC CIK
0001696864

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Microbot Medical Inc.MBOT · Entity 6767DirectorApril 01, 2026April 03, 2026
NovoCure LtdNVCR · Entity 4494DirectorJune 03, 2026June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Microbot Medical Inc.

Report date April 01, 2026 · Filed April 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.37 · Expires 2036-04-01Direct10,000 Reported balance After 2026-04-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-04-01 · Grant · Acquired 10,000 · Balance 10,000

NovoCure Ltd

Report date June 03, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect30,284 Reported balance After 2026-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 30,284

F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03Direct16,999 Reported balance After 2026-06-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999

F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 03, 2026 Filed Jun 5, 2026 20:26 UTC NovoCure Ltd NVCR · Entity 4494 GrantStock Option (Right to Buy) · Derivative 16,999 $0.00 Strike: $16.15 $0.00
Disclosure

SEC source: 0001696864-26-000001 · primarydocument.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,999

Underlying: Ordinary Shares · 16,999 shares

Expires 2036-06-03

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:26 UTC NovoCure Ltd NVCR · Entity 4494 GrantOrdinary Shares 11,610 $0.00 $0.00
Disclosure

SEC source: 0001696864-26-000001 · primarydocument.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,284

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:30 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001493152-26-015148 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock, par value $0.01 per share · 10,000 shares

Expires 2036-04-01

Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:19 UTC NovoCure Ltd NVCR · Entity 4494 GrantStock Option (Right to Buy) · Derivative 33,393 $0.00 Strike: $16.72 $0.00
Disclosure

SEC source: 0001562180-25-004560 · primarydocument.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,393

Underlying: Ordinary Shares · 33,393 shares

Expires 2035-06-04

F1 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

Read SEC document
June 03, 2025 Filed Jun 4, 2025 20:23 UTC NovoCure Ltd NVCR · Entity 4494 SaleOrdinary Shares 999 $17.19 $17,175.61
Disclosure

SEC source: 0001562180-25-004438 · primarydocument.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,674

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price.

Read SEC document
January 28, 2025 Filed Jan 30, 2025 21:30 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $1.93 $0.00
Disclosure

SEC source: 0001493152-25-004279 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock, par value $0.01 per share · 10,000 shares

Expires 2035-01-28

Read SEC document
June 05, 2024 Filed Jun 6, 2024 22:13 UTC NovoCure Ltd NVCR · Entity 4494 GrantStock Option (Right to Buy) · Derivative 6,229 $0.00 Strike: $23.13 $0.00
Disclosure

SEC source: 0001562180-24-004774 · primarydocument.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

Read SEC document
June 05, 2024 Filed Jun 6, 2024 22:13 UTC NovoCure Ltd NVCR · Entity 4494 GrantOrdinary Shares 4,053 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-004774 · primarydocument.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,673

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

F2 · balance_after: Report no longer includes indirect ownership of shares held by filer's adult child. Child no longer shares a residence with the filer.

Read SEC document
November 02, 2023 Filed Nov 6, 2023 21:15 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 74,218 $0.00 Strike: $1.28 $0.00
Disclosure

SEC source: 0001493152-23-039527 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,218

Underlying: Common Stock, par value $0.01 per share · 74,218 shares

Expires 2033-11-02

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:04 UTC NovoCure Ltd NVCR · Entity 4494 GrantStock Option (Right to Buy) · Derivative 12,554 $0.00 Strike: $48.66 $0.00
Disclosure

SEC source: 0001562180-23-005014 · primarydocument.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,554

Underlying: Ordinary Shares · 12,554 shares

Expires 2033-06-06

F1 · derivative.exercise_date: Options to buy 12,554 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders.

Read SEC document
September 21, 2022 Filed Sep 23, 2022 10:39 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 16,637 $0.00 Strike: $5.71 $0.00
Disclosure

SEC source: 0001493152-22-026613 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,637

Underlying: Common Stock, par value $0.01 per share · 16,637 shares

Expires 2032-09-21

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:12 UTC NovoCure Ltd NVCR · Entity 4494 GrantOptions to Buy Ordinary Shares · Derivative 8,700 $0.00 Strike: $77.25 $0.00
Disclosure

SEC source: 0001645113-22-000055 · wf-form4_165489194524345.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,700

Underlying: Ordinary Shares · 8,700 shares

Expires 2032-06-08

F1 · derivative.exercise_date: Options to buy 8,700 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders.

Read SEC document
September 29, 2021 Filed Oct 5, 2021 22:12 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 13,571 $0.00 Strike: $7.00 $0.00
Disclosure

SEC source: 0001493152-21-024670 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,571

Underlying: Common Stock, par value $0.01 per share · 13,571 shares

Expires 2031-09-29

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document
August 05, 2021 Filed Aug 6, 2021 20:44 UTC NovoCure Ltd NVCR · Entity 4494 SaleOrdinary Shares 34 $153.13 $5,206.42
Disclosure

SEC source: 0001645113-21-000101 · wf-form4_162828263563750.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Indirect

Disclosed balance after: 384

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · ownership.nature: Represents shares indirectly beneficially owned by Mr. Madden that are held by his child with whom he shares a residence. Mr. Madden disclaims beneficial ownership of these shares.

Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:22 UTC NovoCure Ltd NVCR · Entity 4494 GrantOptions to Buy Ordinary Shares · Derivative 1,499 $0.00 Strike: $211.89 $0.00
Disclosure

SEC source: 0001645113-21-000078 · wf-form4_162344295339216.xml · derivative · entry 3

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,499

Underlying: Ordinary Shares · 1,499 shares

Expires 2031-06-09

F3 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:22 UTC NovoCure Ltd NVCR · Entity 4494 GrantRestricted Stock Units 814 $0.00 $0.00
Disclosure

SEC source: 0001645113-21-000078 · wf-form4_162344295339216.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,620

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

Read SEC document
March 02, 2021 Filed Mar 4, 2021 22:56 UTC NovoCure Ltd NVCR · Entity 4494 GrantRestricted Share Units 111 $0.00 $0.00
Disclosure

SEC source: 0001645113-21-000034 · wf-form4_161489857586408.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Indirect

Disclosed balance after: 418

F1 · ownership.nature: Represents shares indirectly beneficially owned by Mr. Madden that are held by his child with whom he shares a residence. Mr. Madden disclaims beneficial ownership of these shares.

Read SEC document
November 05, 2020 Filed Nov 9, 2020 22:15 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 2,771 $0.00 Strike: $7.22 $0.00
Disclosure

SEC source: 0001493152-20-020843 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,771

Underlying: Common Stock, par value $0.01 per share · 2,771 shares

Expires 2030-11-05

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:36 UTC NovoCure Ltd NVCR · Entity 4494 GrantRestricted Stock Units 307 $0.00 $0.00
Disclosure

SEC source: 0001645113-20-000117 · wf-form4_159665976375408.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Indirect

Disclosed balance after: 307

F1 · ownership.nature: Represents shares indirectly beneficially owned by Mr. Madden that are held by his child with whom he shares a residence. Mr. Madden disclaims beneficial ownership of these shares.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:09 UTC NovoCure Ltd NVCR · Entity 4494 GrantOptions to Buy Ordinary Shares · Derivative 5,101 $0.00 Strike: $67.89 $0.00
Disclosure

SEC source: 0001645113-20-000088 · wf-form4_159199976247040.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,101

Underlying: Ordinary Shares · 5,101 shares

Expires 2030-06-10

F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:09 UTC NovoCure Ltd NVCR · Entity 4494 GrantRestricted Stock Units 2,541 $0.00 $0.00
Disclosure

SEC source: 0001645113-20-000088 · wf-form4_159199976247040.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,806

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders.

Read SEC document
October 23, 2019 Filed Oct 24, 2019 23:16 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 3,952 $0.00 Strike: $5.06 $0.00
Disclosure

SEC source: 0001493152-19-015938 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,952

Underlying: Common Stock, par value $0.01 per share · 3,952 shares

Expires 2029-10-23

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document
May 22, 2019 Filed May 24, 2019 20:13 UTC NovoCure Ltd NVCR · Entity 4494 GrantOptions to Buy Ordinary Shares · Derivative 6,340 $0.00 Strike: $51.36 $0.00
Disclosure

SEC source: 0001209191-19-032687 · doc4.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,340

Underlying: Ordinary Shares · 6,340 shares

Expires 2029-05-22

F2 · derivative.exercise_date: Options to buy 6,340 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders.

Read SEC document
May 22, 2019 Filed May 24, 2019 20:13 UTC NovoCure Ltd NVCR · Entity 4494 GrantRestricted Stock Units 3,359 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-032687 · doc4.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,265

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders.

Read SEC document
May 21, 2019 Filed May 22, 2019 20:21 UTC NovoCure Ltd NVCR · Entity 4494 Exercise / conversionRestricted Stock Units · Derivative 8,906 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-19-032046 · doc4.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 8,906 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.expiration_date: Fully vested as of the date hereof.

Read SEC document
May 21, 2019 Filed May 22, 2019 20:21 UTC NovoCure Ltd NVCR · Entity 4494 Exercise / conversionOrdinary Shares 8,906 $48.87 $435,236.22
Disclosure

SEC source: 0001209191-19-032046 · doc4.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 21, 2019 Filed Jan 23, 2019 22:43 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 2,326 $0.00 Strike: $8.60 $0.00
Disclosure

SEC source: 0001493152-19-000862 · ownership.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,326

Underlying: Common Stock, par value $0.01 per share · 2,326 shares

Expires 2029-01-21

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document
May 31, 2018 Filed Jun 5, 2018 00:10 UTC NovoCure Ltd NVCR · Entity 4494 GrantRestricted Stock Unit · Derivative 8,906 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-035382 · doc4.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,906

Underlying: Ordinary Shares · 8,906 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.

F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.

F3 · derivative.expiration_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.

Read SEC document
May 31, 2018 Filed Jun 5, 2018 00:10 UTC NovoCure Ltd NVCR · Entity 4494 GrantOptions to Buy Ordinary Shares · Derivative 17,891 $0.00 Strike: $31.45 $0.00
Disclosure

SEC source: 0001209191-18-035382 · doc4.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,891

Underlying: Ordinary Shares · 17,891 shares

Expires 2028-05-31

F1 · derivative.exercise_date: Options to buy 17,891 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.

Read SEC document
December 06, 2017 Filed Dec 8, 2017 22:09 UTC Microbot Medical Inc. MBOT · Entity 6767 GrantStock Option (Right to Buy) · Derivative 38,095 $0.00 Strike: $1.05 $0.00
Disclosure

SEC source: 0001493152-17-014426 · form4.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,095

Underlying: Common Stock, par value $0.01 per share · 38,095 shares

Expires 2027-12-06

F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.